Efficacy and tolerability of oral vinorelbine in metastatic breast cancer
Abstract
The article presents the results of oral use of vinorelbine for the second and third lines of chemotherapy of metastatic breast cancer. Patients received vinorelbine per os 60 mg/m2 1 time per week (1st, 8th, 15th day of treatment), 21 day cycle, with subsequent dose escalation up to 80 mg/m2. The disease control (partial response + stabilization) was achieved in 13 of 17 patients. Oral chemotherapy with vinorelbin has a satisfactory profile of toxicity, can be performed in outpatient department, requires minimal maintenance.
About the Authors
I. A. Korolyova
Samara Medical University ‘REAVIZ’
Russian Federation
Russian Federation
M. V. Kopp
Samara Medical University ‘REAVIZ’
Russian Federation
Russian Federation
Yu. V. Kostalanova
Samara Regional Clinical Cancer Centre
Russian Federation
Russian Federation
A. V. Tarasova
Samara Regional Clinical Cancer Centre
Russian Federation
Russian Federation
A. M. Korolyova
Samara State Medical University
Russian Federation
Russian Federation
References
1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2016. II CA Cancer J. Clin. 2016. Jan-Feb; 66 (1): 7-30.
2. Fisher B., Brown A., Mamounas E. et al. Effect of preoperative chemotherapy on localregional disease in women with operable breast cancer. Finding from National Surgical Adjuvant Breast and Bowel Project B-18. II J. Clin. Oncol. 1997. V. 15. P. 2483-2493.
3. Аничков Н.М. Биологические и клиникоморфологические аспекты учения о метастазировании злокачественных опухолей. II Мед. акад. журнал. 2003. № 1. С. 3-13.
4. Летягин В.Я. Опухоли молочной железы. Клиника, диагностика, лечение. Прогноз: М. 2000. 244 с.
5. Орлова Р.В., Моисеенко В.М. Принципы лекарственного лечения больных диссеминированным раком молочной железы II Практическая онкология. 2000. № 2. С. 19-21.
6. Добровольская Н.Ю. Лекарственная и лучевая терапия в лечении местнораспространенного и диссеминированного рака молочной железы. Дисс.. д-ра мед. наук: 14.00.19 / М. 2007. 204 с.
7. Liu G., Franseen E. Fitch et al. Patients preferences for oral vs intravenous palliative chemotherapy. J. Clin. Oncol. 1997, 15: 110-115.
8. Cannobio L., Boccardo.F., Pastorino G. et al. Phase II study of Navelbine in advanced breast cancer. Semin. Oncol. 1989; 16 (Suppl. 4): 3336.
9. Fumoleau P., Delgado F.M., Delozier T. et al. Phase II trial of weekly intravenous Vinorelbine in first line advanced breast cancer chemotherapy. J. Clin. Oncol. 1993; 11: 1245-1252.
10. Bruno S., Lira Puerto V., Mickiewicz et al. Phase II trial of weekly iv Vinorelbine as a single agent in firstline advanced breast cancer chemotherapy. Am. J. Clin. Oncol., 1995, v. 18, N 5, pp. 3925.
11. Garcia Conde J., Lluch A., Martin M. et al. Phase II trial of weekly IV Vinorelbine in firstline advanced breast cancer chemotherapy. Ann. Oncol. 1994; 5: 854-857.
12. Э.К. Возный, И.В. Поддубная, М.М. Константинова, И.А. Королева, М.В. Копп и др. Комбинация навельбина и доксорубицина в химиотерапии первой линии распространенного рака молочной железы. II Русский медицинский журнал. Том 10, № 24, 2002. с. 1126-1132.
13. Strada M.R., Palumbo R., Bernardo A., et al. Intravenous or Oral Vinorelbine Plus Capecitabine As First-Line Treatment in HER 2-Metastatic Breast Cancer: Joint Analysis of 2 Consecutive Prospective Phase II Trials. Clin. Brest. Cancer 2012 Volume 12, Issue 1, Pages 30-39.
14. Freyer.G, Delozier T., Lichinister M., Gedouin D., et al. Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J. Clin. Oncol. 2003, 21 (1): 35-40.
15. Trillet-Lenoir V.S.H., Delozier T., Koralewski P., et al. Oral vinorelbine in metastatic breast cancer. long term results of 2 phase II studies. Eur. J. Cancer 2004, 2 (3): 137, abstract 279.
16. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. March 31, 2003 (http: IIctep.cancer.gov), Publish Date: August 9, 2006.
Review
For citations:
Korolyova I.A., Kopp M.V., Kostalanova Yu.V., Tarasova A.V., Korolyova A.M. Efficacy and tolerability of oral vinorelbine in metastatic breast cancer. Medical alphabet. 2017;2(25):35-38. (In Russ.)
Views:
462
Email this article 